Date
Title
Date
11/10/22
Title
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
Date
11/08/22
Title
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
Date
11/04/22
Title
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Date
11/03/22
Title
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Date
10/10/22
Title
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
Date
09/19/22
Title
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
Date
09/07/22
Title
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
Date
09/06/22
Title
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Date
08/04/22
Title
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Date
08/02/22
Title
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides